Pfizer Looks To Give J&J/Merck Heartburn With Zantac 150 Switch
This article was originally published in The Tan Sheet
Pfizer Consumer Healthcare's Rx-to-OTC switch of Zantac 150 appears to be a belated attempt to counter Johnson & Johnson/Merck's approval of Maximum Strength Pepcid AC last year
You may also be interested in...
New heartburn prevention/relief product Maximum Strength Pepcid AC will hit shelves Oct. 17, following FDA approval of the new dosage Sept. 24, according to Johnson & Johnson/Merck
Wal-Mart is shipping "pre-awareness" promotional kits for Procter & Gamble's Prilosec OTC (omeprazole) to its stores in anticipation of the heartburn prevention drug's Sept. 15 launch
Glaxo Wellcome has agreed to sell trademark rights and other controls over the marketing of OTC Zantac 75 to Warner-Lambert Consumer Group in order to complete its merger with SmithKline Beecham in accordance with a proposed consent order issued by the Federal Trade Commission Dec. 18.